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INTRODUCTION 
Financial support for vaccination-related projects is justified 
for a number of reasons, but primarily because of the enormous 
human and economic benefits that result from funds spent on 
disease prevention by immunization - probably the greatest return 
for any health-care dollar. IDRC should play a part in such 
financing because there are vaccine-related needs that would 
probably not otherwise be met by other granting agencies,which 
often concentrate their attention on vaccine development and 
large scale trials of immune responses and efficacy. While these 
are vital aspects, various.local circumstances may necessitate 
some modification of generally accepted vaccination policies or 
procedures, and investigation of such instances may be very 
important to optimize the effectiveness of vaccination policies 
in a particular country or region. 
In this report, an assessment has been made of the various 
categories of project that have been funded for vaccination- 
related topics since 1980, and also of applications currently 
under consideration. A proposed strategy for the Centre in 
dealing with future activities in this field has been drawn up, 
and an outline of a recommended policy is given. 
VACCINATION-RELATED PROJECTS SUPPORTED 1980 TO DATE 
For purposes of comment, these have been classified into six 
categories. 
1. Data collection ~ertinent to the development or modifi-cation 
of vaccination ~olicv in the reci~ient countrv 
The vaccines (and countries) were: 
Hepatitis B (Malaysia, Philippines, St. Kitts, 
Mozambique, 'China) 
Polio and DPT (Jamaica, Thailand) 
Rubella (Malaysia) 
Japanese encephalitis (Thailand) 
Measles (Philippines) 
Comment - Vaccination policies have to be devised for developing 
countries because policies formulated for North America 
and Europe are often inappropriate since there are many 
differences in disease incidence, health care delivery 
systems, socio-economic factors etc. To devise an ap- 
propriate policy, data must be collected and analyzed 
to enable the optimal dosage to be given at practicable 
and appropriate time intervals. Studies such as those 
listed above provide such assistance to the authorities 
of the countries concerned and should continue to be 
supported with high priority. 
It may be appropriate for apparently similar studies to 
be undertaken in more than one country. Local 
conditions can affect immune responses. For example, 
in some countries certain enteroviruses may commonly 
circulate in a country and cause widespread symptomless 
infection of the intestinal tract. Such infected 
persons may not respond to a dose of oral polio-vaccine 
(OPV) and as few as half the recipients of an OPV 
course may be rendered immune. Whereas in another 
country where such endemic viruses are uncommon, more 
than 90% of recipients may become immune after a 
course. Where it is known or believed that local 
circumstances may affect the response to vaccines, 
studies are well worth support. 
2. Evaluation of the effectiveness of vaccines and vaccine 
proqrammes 
BCG (Korea, Haiti, Kenya) 
DPT and Polio (Thailand) - a vaccine trial . centre. 
Comment - Assessment of the effectiveness of BCG has been the 
subject of some major research projects, eg. India. 
Results have been controversial. It is not a suitable 
subject for small scale studies, and is not recommended 
for IDRC support. Research on TB incidence is useful 
but trends should not be ascribed to BCG exclusively 
since many other factors play a role. 
The support for a vaccine Centre in Thailand is 
commended. 
3. Study of factors which mav influence the immune response to 
vaccines 
- 
Nutritional state - (Senegal, Colombia) (BCG, measles, 
tetanus ) 
Schistosomiasis - (Egypt) (Hepatitis B) 
Comment - These factors may interfere with development of 
immunity and necessitate adjustment of dosage and 
schedules to achieve the best response. This may be of 
great importance in some countries and regions, and 
research locally into the effects and ways to rectify 
them should be supported. 
4. Support for vaccine production and development 
Yellow fever (Brazil, Colombia, Nigeria) 
Comment - Improvements in vaccine production facilities were 
supported. This is not research and might be more 
properly funded by CIDA. A component in Brazil, 
however, on developing a cell culture methodology for 
vaccine production, was appropriate for support. 
5. Maintenance of vaccine ~otencv 
Measles (PATH, USA) 
Comment - Evaluation of a new time-temperature visual indicator 
of inproper handling procedures for vaccine was a 
useful exercise and worth funding. Deterioration of 
vaccines during storage or transport is a major problem 
in developing countries and a simple indicator 
certainly deserved field evaluation. 
6. Non-microbial vaccine research 
Anti-pregnancy (India, Chile) 
Comment - I have no expertise in this subject but it appears to 
be exciting and of great potential, though it is a 
lengthy and expensive project. It is progressing. 
PIPELINE PROJECTS 
These are categorized numerically as in the previous section. 
1. Data collection pertinent to vaccination ~olicv 
Hepatitis B (Malaysia/S. Korea/Philippines) 
Measles (Cameroon, Sudan) 
Comment - The tri-centre hepatitis study has a number of objec- 
tives and is a composite of three distinct projects. 
The portions that deal with the integration of an 
infant vaccination schedule into the EPI programmes is 
pertinent and topical, and is relevant to the Centre's 
objectives. The Korean sub-project, however, includes 
a clinical trial of dosage schedules and efficacy of 
two Korean plasma-derived HE vaccines, and such a 
proposal would not normally be regarded as suitable for 
IDRC support. 
The measles vaccine projects are scientifically sound 
evaluations of vaccination at 5 or 6 months of age - 
either with a higher dose or with the more potent 
Edmonston-Zagreb Virus strain - and are appropriate 
subjects. A similar project in the Philippines has 
already been accepted by IDRC. This is a subject of 
much current interest and other studies may be nearing 
completion. It may be prudent to make enquiries in 
this regard before reaching a decision on these two. 
(see Appendix 1) 
2. Evaluation of effectiveness of vaccines 
BCG (Zambia, Uganda) 
Comment - As indicated in my earlier comments, BCG efficacy 
studies are not considered appropriate subjects for 
IDRC support. 
3. Studv of factors influencins the immune resgonse 
Hepatitis B - Schistosomiasis (Egypt) 
Comment - This application was prompted by an observation of a 
decreased antibody response to HB vaccine in infants 
of mothers infested with S. mansoni. Further study of 
this problem is necessary since it would pose a major 
difficulty in designing vaccination schedules for 
infants in regions with widespread schistosome infesta- 
tion. I believe this is a highly appropriate topic for 
IDRC support. 
4. Support for vaccine ~roduction and development 
Japanese encephalitis (Thailand/Canada) 
Comment - This proposal concerns molecular biological research 
into the possibility of devising a synthetic peptide 
vaccine and, if successful, the transfer of the tech- 
nology to Thailand. The initial work will be highly 
academic research in Canada and the project is not 
recommended for IDRC support. 
5. Maintenance of vaccine potency 
There are no pipeline projects in this category. 
6. Non-microbial vaccine research 
Snake-bite vaccine (Thailand) 
Comment - While this is outside my areas of experience, the 
proposal is interesting and seems to be appropriate for 
financial support from the Centre. 
CONSIDERATIONS RELEVANT TO FUTURE STRATEGY REGARDING VACCINATION- 
RELATED APPLICATIONS 
Applications for financial support expected to be received by 
IDRC in relation to vaccines and vaccination are likely to 
include proposals for research into the following aspects: 
-improvements in existing vaccination programmes 
-design of new vaccination policies and programmes 
-evaluation of the impact of vaccination programmes 
These three aspects will b,e briefly reviewed below and from this 
discussion topics that seem most appropriate to the objectives of 
IDRC will be chosen in the formulation of a policy for the 
future. 
Proposals that include research projects that are regarded as the 
responsibility of the developer or manufacturer of a vaccine, 
such as trials of immunogenicity, safety and efficacy, or major 
projects such as the establishment of vaccine production 
facilities in developing countries,are considered inappropriate 
for IDRC support and are not commented upon. 
A. Improvements in Existing Vaccination Programmes 
This covers a broad class of possible proposals. Some of the more 
relevant aspects have been chosen for comment. 
Protection of children at an earlier age than at  resent 
Infants should be immunized at the earliest time after birth 
that vaccine can be given safely and stimulate a reliable 
protective response. Antibody derived from the mother may 
interfere with the response to early vaccination with some 
immunizing agents but improved, more potent products are 
becoming available that permit effective immunization at 
earlier ages than hitherto. An example, presently under IDRC- 
supported trial, is the Edmonston-Zagreb measles vaccine which 
it is hoped can be effectively administered at 5 months of age 
rather than at the current 9 months. 
The response to early vaccination with some vaccines will be 
dependent on maternal antibody, as indicated, but the propor- 
tion of mothers with antibodies to various organisms varies 
from one generation to the next, particularly in a country 
where hygiene and socio-economic conditions have changed in 
recent decades. Thus early vaccination deserves constant 
review. The potential to save infant lives is great and appli- 
cations deserve serious consideration. 
2 .  S t u d i e s  of t h e  e f f e c t  on vacc ine - induced  immunity of r e c t i -  
f i a b l e  o r  t r e a t a b l e  c o n d i t i o n s  
The n u t r i t i o n a l  s t a t e  o r  t h e  p r e s e n c e  of a n  i n f e c t i o n  o r  
i n f e s t a t i o n ,  whether  symptomatic' o r  n o t ,  may a f f e c t  t h e  r e s -  
ponse t o  v a c c i n a t i o n .  
P r o p o s a l s  may i n v o l v e  r e s e a r c h :  ( a )  t o  d e t e r m i n e  t h e  e f f e c t  o f  
m a l n u t r i t i o n  o r  a  p a r a s i t i c  i n f e c t i o n  ( e . g .  s c h i s t o s o m a )  on  
t h e  immune r e s p o n s e  o r  ( b )  t o  modify t h e  v a c c i n a t i o n  s c h e d u l e ,  
such a s  by a  l a r g e r  d o s e  o r  more d o s e s ,  s o  a s  t o  compensate 
f o r  t h e  a d v e r s e  c o n d i t i o n  i f  it c a n n o t  be r e c t i f i e d  o r  e r a d i -  
c a t e d .  Both a s p e c t s  of r e s e a r c h  a r e  , l i k e l y  t o  l e a d  t o  improved 
immunity i n  t h e  p o p u l a t i o n  c o n c e r n e d ,  which may v a r y  from a  
s m a l l  community t o  a  l a r g e  r e g i o n .  I t  i s  wor thwhi le  r e s e a r c h .  
3 .  De te rmina t ion  of t h e  minimum e f f e c t i v e  d o s e  of a  v a c c i n e  
Some r e c e n t l y  developed v a c c i n e s  ( e . g .  h e p a t i t i s  B )  have been 
r e p o r t e d  t o  be e f f e c t i v e  i n  s m a l l e r  d o s e s  t h a n  a r e  g e n e r a l l y  
recommended. I t  i s  l i k e l y  t h a t  workers  i n  some d e v e l o p i n g  
c o u n t r i e s  w i l l  wish t o  e x p l o r e  t h i s  a s p e c t  i n  t h e i r  own j u r i s -  
d i c t i o n  s i n c e  i t  w i l l  r educe  c o s t s  and h a s  t h e  p o t e n t i a l  f o r  
r e d u c i n g  t h e  i n c i d e n c e  of a d v e r s e  r e a c t i o n s .  P r o p e r l y  d e s i g n e d  
s t u d i e s  t o  s t u d y  reduced dosage  a r e  s u i t a b l e  f o r  s u p p o r t .  
4 .  Comaarat ive s t u d i e s  of improved immunizing p r e p a r a t i o n s  
There  may be more p o t e n t  v a c c i n e s  t h a n  t h o s e  p r e s e n t l y  i n  u s e  
( e . g .  enhanced po tency  i n a c t i v a t e d  p o l i o  v a c c i n e -  IPV; Edmon- 
s ton-Zagreb  meas les  v a c c i n e )  o r  newly marketed  combina t ions  of  
v a c c i n e s  (DPT p l u s  enhanced p o t e n c y  IPV) .  Combinat ion "cock-  
t a i l s "  have t h e  v i r t u e  of o f t e n  p e r m i t t i n g  s h o r t e n i n g  of a  
s c h e d u l e  and r e d u c t i o n  i n  t h e  number of m o t h e r / c h i l d  v i s i t s .  
Another  p r e p a r a t i o n  which may be  a v a i l a b l e  i n  a  few y e a r s  i s  
a n  a c e l l u l a r  p e r t u s s i s  v a c c i n e ,  which i s  e x p e c t e d  t o  r e p l a c e  
t h e  whole c e l l  p e r t u s s i s  v a c c i n e  t h a t  i s  a  component of DPT. 
C l i n i c a l  and e f f i c a c y  t r i a l s  of a c e l l u l a r  p e r t u s s i s  v a c c i n e  
and of  enhanced po tency  I P V  a r e  e x p e c t e d  t o  b e  major  p r o j e c t s  
t h a t  would be  beyond t h e  scope  and o b j e c t i v e s . o f . I P R C ,  b u t  
a p p l i c a t i o n s  r e l a t e d  t o  more l o c a l ' i s s u e s  of t h e i r  usage  i n  
c e r t a i n  c o u n t r i e s  may be expec ted  and might  b e  a p p r o p r i a t e .  
B .  Des i sn  of  new v a c c i n a t i o n  p o l i c i e s  and prosrammes 
A s  new v a c c i n e s  become a v a i l a b l e ,  t h e i r  r o l e  i n  d i s e a s e  
p r e v e n t i o n  i n  each c o u n t r y  has  t o  b e  d e t e r m i n e d .  The c o s t s  and 
benefits need to be evaluated and will vary with the incidence of 
disease and many other factors, Even when widespread or universal 
use of a vaccine is considered desirable, matters of scheduling 
and integration with other vaccination programmes or health care 
visits remain to be determined. The possible. integrat.ion of 
hepatitis B vaccine into the EPI is an example which has already 
led to a proposal to IDRC. It is a relevant and important matter 
that requires research for its resolution. 
Other new vaccines that lie ahead include oral typhoid vaccine 
and oral cholera vaccine. When these have been proven safe and 
effective, their role in developing countries will have to be 
defined. To whom should th,ey be given and when? Such proposals 
should be appropriate for support from the Centre since local 
circumstances will probably be an important consideration in the 
decisions. 
C. Evaluation of the im~act of vaccination proqrammes 
Costly major immunization programmes are in effect in many 
countries. It is important to assess the impact of the programmes 
on the incidence of diseases that are their targets. Only in this 
way can deficiencies be detected, their cause determined and 
remedial measures be taken. 
Research projects devised to develop effective and practicable 
disease surveillance systems and vaccination record systems are 
necessary in many countries to ensure that data collected is 
valid and, when appropriately analyzed, will lead to meaningful 
conclusions. This monitoring is of great importance in any 
determination that the funds expended on vaccination are having 
the desired and optimal effect. Innovative proposals deserve 
support. 
Another means of assessing that vaccine administration is being 
effectively performed with potent vaccine is the detection of 
serum antibody following vaccination. Laboratory testing is often 
unavailable or is much too expensive for this purpose, but a 
number of simple, rapid, economical and highly specific devices 
or "kits" are becoming available by which antibody can be 
detected. If these can be shown by research studies to be suit- 
able for field use, a valuable rapid means of assuring the 
quality of the immunizing procedure would be available. The 
specificity is usually determined by a monoclonal antibody 
component in the kit. Support for field use of rapid economical 
antibody detection kits would be of appropriate. 
Improvements in procedures for assessing the impact of vaccina- 
tion programmes, both EPI and non-EPI, on disease incidence 
would be of great value in many countries. Innovative ideas that 
might meet this objective should be encouraged and supported. 
RECOMMENDATIONS FOR A POLICY FOR SUPPORT OF VACCINATION-RELAT' 
PROPOSALS 
It is recommended that the Centre provide support for research 
projects designed to facilitate the optimal use of vaccines in 
preventing disease in the recipient country. 
The unique status and activities of IDRC could best be utilized 
by giving particular emphasis and priority to aspects that may 
involve uncommon or unusual local circumstances in a country or 
region which might require modifications of policies or 
programmes in general use in developing countries. 
The categories of application that deserve support have been 
divided into two groups: one "recommended for support" and the 
other "suitable for support". This distinction is made on the 
likelihood that the granting agencies would receive and approve 
applications on the topics concerned. Categories of proposal in 
both groups would provide practical useful information of value 
in developing countries, but for those in the "suitable for 
support" group, care should be taken to ensure that there is no 
superfluous duplication of studies already in progress, as they 
are of nore general scope and less dependent upon local circum- 
stances. 
Catesories of proposal - recommended for support: 
1 .  Strategies on the optimal usage of vaccines in communities, 
countries or regions in which conditions are known or 
believed to exist which may diminish the immune response. 
Such conditions may include severe malnutrition, a high 
incidence of certain infections or infestations (whether 
apparent or inapparent) etc. 
2. Studies of the most effective use of newly licenced vac- 
cines, such as oral typhoid vaccine and oral cholera vac- 
cines which are expected to become available in the near 
future. Determination of the target population most likely 
to benefit from such vaccines in areas of both high and low 
endemicity would be valuable. (,,, Appendix 
3 .  Proposals relating to evaluation of the impact of vaccination 
programmes. These may include a variety of topics from 
innovative ideas regarding record-keeping or 'disease sur- 
veillance appropriate for the locality or country to trials 
of the field use of simple antibody detection kits that 
would assist in determination of immunity in areas without 
laboratory support. 
Cateqories of ~ r o ~ o s a l  suitable for su~gort 
These include subjects that may be expected to be supported by 
other funding agencies also. 
1. Proposals for the immunization of children at an earlier age 
than is now undertaken. 
2. Studies on the optimum usage of combination of vaccines in a 
single preparation. 
3. Determination of the minimum dose of a vaccine that will 
reliably confer immunity. 
4. Comparative studies of newly available and potentially more 
potent vaccines with existing vaccines. 
5. Feasibility and design studies for new vaccination program- 
mes, such as addition of hepatitis B vaccine to the EPI. 
Categories of ~ r o ~ o s a l  that will senerallv not be suitable for 
funding 
1. Development or clinical trials of new or improved vaccines. 
2. Large-scale efficacy trials of new or existing vaccines. 
3. Establishment of or modifications to vaccine-production 
facilities. 
4. Studies that would merely confirm existing knowledge of vac- 
cines or vaccine programmes. 
APPENDICES 
APPENDIX 1 Trials of Edmonston-Zaqreb Measles Vaccine 
A number of studies of the serological response to the 
Edmonston-Zagreb strain of measles vaccine in infants less than 
9 months of age are being undertaken in developing countries. 
The following list is of those which staff at the Centers for 
Disease Control, Atlanta, believe will be completed by July 
1989 (except Haiti - probably October 1989; and Gambia and Peru, 
date uncertain). An indication of the supporting or sponsorin4 
agency or institution is given. 
Mexico - USAID; CDC and Ministry of Health 
Senegal - Task Force on Child Survival 
Gambia - Medical Research Council, U.K. 
Tanzania - R.I.T. 
Haiti - Johns Hopkins University 
Zanzibar - Save the Children Fund; R.I.T. 
Peru - Johns Hopkins University 
Togo - (unavailable) 
The list is not comprehensive, but is illustrative of the 
multiplicity of studies currently being completed. 
APPENDIX 2 Newly Developed Oral Vaccines for Enteric Diseases 
Licensure is likely within the next few years of new typhoid 
and cholera vaccines which are administered orally. For example, 
the Ty2la typhoid vaccine has been tested with encouraging results 
in Egypt and is now being studied in Chile, a country of high 
endemicity. In Chile, the most appropriate usage may be mass 
vaccination of school-children (Ferreccio et al. J. Infect. Dis., 
1989, 159, 766), whereas in countries with different epidemiological 
patterns a quite different approach may be better. Likewise, 
the optimal dosage in areas with different degrees of endemicity 
has yet to be determined. Furthermore, the value of a combined 
cholera-typhoid oral vaccine remains to be established. Many 
of these aspects may, in the future, be appropriate subjects for 
IDRC support, as national authorities seek data on which to 
decide the most effective use of these new agents in their own 
jurisdictions. 
